Veracyte Inc
(NAS:VCYT)
$
59.92
+1.335 (+2.28%)
Market Cap: 4.78 Bil
Enterprise Value: 4.38 Bil
PE Ratio: 54.98
PB Ratio: 3.56
GF Score: 75/100 Veracyte Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021 / 07:30PM GMT
Release Date Price:
$46.91
(-2.76%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst
Hey, everyone. Good afternoon. Thanks for joining us at our Healthcare Conference. I'm Tejas Savant, and I cover the Life Science Tools and Diagnostics sector here at Morgan Stanley. Delighted to have Veracyte join us today. And representing the Company are Marc Stapley, CEO; and Rebecca Chambers, CFO. Welcome to you both guys.
Before we begin, just some important disclosures I need to read out. Please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.
Marc, I believe you want to go through the safe harbor as well.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot